Immune-enriched TME phenotype as potential response biomarker
Tumors, cancer, tumor, non-IE
TUMORS, CANCER, TUMOR, REGRESSION
Next, based on immune cell abundance and the enrichment pathway of cancer hallmarks from the Molecular Signatures Database between well and poor responders (Extended Data Fig. Tumors of the IE subtype exhibited more pathological tumor regression than non-IE subtypes, as exemplified by the finding that IE subtype was detected in 62.5% (5/8) of well responders compared with only 10% (1/10) of poor responders (Fig. 